Myopia - Pipeline Insight, 2024

Myopia - Pipeline Insight, 2024

DelveInsight’s, “Myopia - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myopia: Understanding

Myopia: Overview

Myopia, or nearsightedness, is a common refractive error characterized by difficulty seeing distant objects clearly. It is the most common in children and young adults, with a global prevalence that has been increasing, particularly in certain ethnic groups. The etiology of myopia is related to the axial length of the eye and the emmetropization process, which can lead to rapid progression to myopia in children with a large axial length at birth. The prevalence of myopia varies globally, with the highest rates in Asians, followed by Hispanics, African Americans, and Caucasians. The classification of myopia is essential for its appropriate management, with axial myopia being the most common type observed in clinical practice, caused by an increase in the axial length of the globe. Other types include meridional myopia, which is related to myopic astigmatism, and lenticular myopia, which is associated with changes in the crystalline lens. The severity of myopia is categorized as mild, moderate, and severe based on the refractive error. The prolonged use of digital screens among children has been linked to the increased incidence and accelerated progression of myopia. The prevalence of myopia in children aged 5–17 years varies globally and is the highest in Asians, followed by Hispanics, African Americans, and Caucasians. The high prevalence in adults has been attributed to the presence of the lenticular component.

The symptoms of myopia, or nearsightedness, include difficulty seeing distant objects clearly, which can lead to squinting, blurred vision for distant objects, and eye strain. Individuals with myopia may also experience headaches, particularly after focusing on distant objects for extended periods. In children, symptoms may manifest as holding books or digital devices close to the face, sitting very close to the television, or a decline in academic performance due to difficulty seeing the whiteboard or screen clearly. It's important to undergo a comprehensive eye examination by an optometrist or ophthalmologist to diagnose myopia and assess its severity, as the condition can be effectively managed with corrective lenses or refractive surgery.

The diagnosis of myopia, or nearsightedness, involves a comprehensive eye examination, which includes tests such as visual acuity assessment to measure the sharpness of vision, a refraction test to determine the correct prescription for glasses or contact lenses, and a slit-lamp exam to assess the eye's internal structures. Your eye care specialist may also inquire about your medical history, perform an examination of the inner eye, and measure the pressure within your eye. These steps help in accurately diagnosing myopia and determining the most appropriate treatment, which may include eyeglasses, contact lenses, or refractive surgery.

“Myopia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.

Myopia Emerging Drugs Chapters

This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myopia Emerging Drugs

• SYD-101: Sydnexis

SYD-101 is an investigational low-dose atropine sulfate ophthalmic solution, 0.01% and 0.03%, designed to achieve efficacy, stability, and reduce discomfort for improved treatment continuity, according to studies on the treatment of childhood myopia. While published reports have shown low concentrations of compounded atropine to be effective, these solutions are limited by short shelf life and remain only stable if markedly acidified, which can also cause excessive burning and stinging in children, according to several studies on atropine for myopia. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myopia.

• MicroPine: Eyenovia

MicroPine is a proprietary microdose formulation of atropine used in our Optejet dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. It is believed that Eyenovia’s delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. Eyenovia is evaluating MicroPine in Phase III program in its CHAPERONE study.

Further product details are provided in the report……..

Myopia: Therapeutic Assessment

This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Myopia

There are approx. 8+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Sydnexis.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.

Myopia Report Insights

• Myopia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myopia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myopia drugs?
• How many Myopia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myopia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myopia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myopia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sydnexis
• Sunhawk Vision Biotech
• Vyluma
• Eyenovia
• Cloudbreak Therapeutics
• Stuart Therapeutics

Key Products

• SYD-101
• SHJ 002
• NVK-002
• Atropine micro-formulation
• CBT-009
• Research programme: Myopia

Show more